Nevrargenics announces a new peer-reviewed publication in the American Chemical Society's journal Omega, highlighting the unique mechanism of its next-generation RAR modulators and their promise in tackling neurodegenerative diseases like ALS and Alzheimer’s.
Our Chief Medical Officer, Dr Tony Lockett, has published a series of articles on clinical trials setting out his ideas about new approaches to trial design and ethics. The links allow to view and download the articles until June 17, 2025.
A new article was published in the special issue of the International Journal of Molecular Sciences, on the potential therapeutic application of Ellorarxine for the treatment of neurodegenerative disorders.
Nevrargenics is pleased to have prepared an outline explaining the company's approach in developing our drugs, with specific focus on Ellorarxine™ for Motor Neuron Disease (MND or ALS). This can be found here: Link
Nevrargenics' CEO, Prof ANdy Whiting and Chief Medical Officer, Dr Tony Lockett, giving an interview at the Podcast of The Mark Sommerville Foundation for Motor Neuron Disease.
The Neuro Rehab Times ("NR Times"), published an article on Nebvargenics' lead drug candidate with the title "A pioneering study has revealed promising results for a new treatment targeting motor neurone disease (MND)".
Durham University publishes new findings on Ellorarxine™, Nevrargenics' breakthrough drug for Motor Neurone Disease, highlighting its potential for neuroprotection, neuroplasticity, and neurorepair in combating MND.
A new Pharmaceutical Manufacturer article highlights the neuroprotective effects of Ellorarxine™ in disease models, supporting its development for ALS and MHRA advice for upcoming human trials.
As a company dedicated to the fight against neurodegeneration, we at Nevrargenics commend all efforts that push the boundaries of treatment for these devastating diseases.
Bionow Neuroscience Conference, Sheffield, 17th July 2024. Our CEO, Prof Andy Whiting, presented the potential role that Nevrargenics might play in developing truly disease modifying drugs.
Nevrargenics proudly participated at a prestigious event in London, right across from the Big Ben and next to St Thomas's Hospital. The event brought together a dynamic group of investors.
Latest overview by Arron Aatkar, healthcare analyst at Edison Group, the leading content-led investor relations business.
The Scientific Advice meeting with the UK Medicines and Healthcare Products Regulatory Agency (MHRA) was held to discuss Nevrargenics’ Motor Neurone Disease drug candidate, NVG0645.
Research Features published an article on us entitled "Nevrargenics: Neuroprotection, neuroplasticity, and neurorepair" about the background to, and summary of, our drug development programme.
We were delighted to take part in Bio Europe Spring 2023 in Basel, Switzerland and have over 30 one-to-one meetings with pharmaceutical companies for potential deals.
Prof Andy Whiting in an interview with Prof. Susan Duty, PhD, FBPhS, from King's College London on Parkinson's.
Nevrargenics participates in the first TRICALS workshop at Schiphol, Netherlands, on ALS since the COVID pandemic.
Nevrargenics launches efficacy studies on MS and ALS models through Experimentica and Charles River respectively.
CEO Andy Whiting gives an interview to Liza Laws, Senior Editor of Labiotech about neurodegeneration and Nevrargenics's drugs.
Research collaboration launch with Professor Susan Duty at King’s College, looking the application of our drugs in Parkinson’s disease models.
Nevrargenics acquires its own premises for the development of its offices and laboratories on Mandale Park in Durham.
Two (once weekly and twice weekly dosing), 28 day tox studies were completed on NVG0645 showing a potential therapeutic window.
Nevrargenics reports that lead drug candidate provides neuroprotection in a 6-hydroxydopamine model of Parkinson’s disease.
Nevrargenics reports multi-neuro-restorative and protective effects using lead drug as a new therapeutic strategy for ALS.
